CenterBook Partners LP Purchases New Position in Medpace Holdings, Inc. $MEDP

CenterBook Partners LP purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 6,296 shares of the company’s stock, valued at approximately $3,237,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MEDP. Clarkston Capital Partners LLC purchased a new stake in shares of Medpace during the 2nd quarter valued at about $40,569,000. Brighton Jones LLC increased its stake in Medpace by 160.4% during the third quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock worth $2,087,000 after acquiring an additional 2,501 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Medpace by 150.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock valued at $8,080,000 after purchasing an additional 9,117 shares during the period. Cibc World Market Inc. bought a new stake in shares of Medpace in the 3rd quarter valued at approximately $5,033,000. Finally, Baillie Gifford & Co. boosted its holdings in shares of Medpace by 12.0% in the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after purchasing an additional 62,503 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of Medpace in a research report on Wednesday, January 28th. Mizuho set a $582.00 price target on Medpace in a research note on Wednesday, February 11th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and reduced their price objective for the stock from $462.00 to $419.00 in a research note on Wednesday. Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, Wall Street Zen upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Saturday, January 17th. Four research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average target price of $483.45.

Medpace Trading Up 4.2%

NASDAQ MEDP opened at $446.17 on Thursday. The stock has a market capitalization of $12.66 billion, a price-to-earnings ratio of 29.16, a PEG ratio of 2.05 and a beta of 1.42. The stock has a 50-day moving average of $560.49 and a 200 day moving average of $538.45. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.49. The business had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The company’s revenue was up 32.0% compared to the same quarter last year. During the same period last year, the firm posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO August J. Troendle sold 668 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $590.69, for a total value of $394,580.92. Following the completion of the sale, the chief executive officer directly owned 646,184 shares in the company, valued at $381,694,426.96. This represents a 0.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Susan E. Burwig sold 20,000 shares of the business’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total transaction of $12,183,000.00. Following the transaction, the vice president owned 27,500 shares in the company, valued at $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 226,603 shares of company stock valued at $137,084,658 in the last 90 days. 20.30% of the stock is owned by insiders.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.